Christopher Flores

Vice President, Glutamatergic Pathway Area Leader, Janssen Pharmaceutical Companies of Johnson & Johnson

Christopher M. Flores, Ph.D., currently leads a cross-functional team within Janssen’s Neuroscience Therapeutic Area in maximizing the benefit to patients from the company’s glutamatergic medicines.  Chris originally joined Johnson & Johnson in 2002 and over the next 16 years held several executive positions within its pharmaceutical and consumer sectors, including Head of Pain Discovery, Senior Director of External Innovation and Pain Franchise Strategy Leader for Janssen Neuroscience as well as Head of Emerging Science and Innovation Strategy for Johnson & Johnson Consumer R&D. 

Before joining Johnson & Johnson, Chris was a P.R.A.T. Fellow at the National Institute of Neurological Disorders and Stroke, an Assistant Professor of Oral Sciences at the University of Minnesota and a tenured Associate Professor at the University of Texas Health Science Center at San Antonio in the Departments of Pharmacology and Endodontics, where he was also Director of Research. For the better part of his 35-yr career in government, academia and industry, Chris has contributed substantively to our mechanistic understanding of pain and neurogenic inflammation at the molecular, cellular, system and behavioral levels and has led the discovery of several new molecular entities that are at various stages of development for the treatment of pain.

Chris’ broad expertise in basic neuroscience, pharmaceutical R&D and open innovation models have led to numerous invitations to give external presentations as well as to serve on expert panels and NIH study sections. He is the author of more than 80 original scientific articles and book chapters on a diverse range of neuroscientific and pharmacologic topics and inventor on more than 40 issued patents.  He was a principal architect of the Massachusetts Neuroscience Consortium and an industrial Co-Chair for the Public-Private Partnership of the NIH HEAL Initiative to combat the opioid crisis; and he has served as a member of the editorial boards for Life Sciences, Molecular Interventions and the Journal of Opioid Management.